- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02544464
Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery?
Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile and the Recovery of Hemoglobin in Total Knee and Hip Arthroplasty Surgery?
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Participation and recruitment: Patients undergoing elective total knee arthroplasty due to osteoarthritis will be interviewed for participation and recruited after providing written informed consent.
Randomization and group allocation:
All recruited patients will be given patient identification number (PIN) for the present study of 01-77 according to their order of interview and recruitment.
Investigators will prepare 33 yellow and 34 green cards, which will be inserted in 77 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 77 (Envelop number).
After printing the envelope number outside envelope, all sealed envelopes with cards will be conveyed to and kept in pharmacy department.
Preparation and Administration of study drug:
Pharmacist will open the envelope with the number same to PIN and check the color of the card inside at study on operation day.
According to the color of the card, IV-iron or placebo will be prepared for the patient: IV-iron for yellow card; placebo for green cards, respectively.
The study drug was employed as "open labelled".
IV-iron or placebo will be infused through already established intravenous line within 30 min after anesthesia induction by attending anesthesiologist who is aware of the patient's group-allocation.
Patient data and statistical analyses:
The information regarding the patient's group allocation will be kept in the pharmacy department till the end of the study and conveyed during the data analyses after completion of the 77th patient participation and discharge.
Patient's data PaO2, FiO2, Hb, intra-op and postop-transfusion amount, intraop- and postop-bleeding amount will be determined from the patients' medical record after patient's discharge.
All statistical analyses will be performed after the 77th patient's discharge and data acquisition.
Surgical procedures:
All surgical procedures will be performed using standardized institutional anesthetic and surgical protocols, antibiotic and antithrombotic prophylaxis, transfusion protocols, and post-operative analgesia.
All TKA will be performed using a pneumatic tourniquet, which is deflated after wound closure. Closed suction drains, which are removed on the second post-operative day, will be placed in all operations.
Transfusion protocol:
Following allogenic blood transfusion protocol will be uniformly applied by anesthesiologists and surgeons to all patients in the operating theater, the post-operative anesthesia care unit, and the ward for the entire duration of hospitalization: blood transfusion of packed RBC will not be performed unless patient's Hb level is < 9 g/dL without any signs and/or symptoms of acute anemia such as hypotension, tachycardia, tachypnea, dizziness, and fatigue.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Seoul, Corea, república de
- Konkuk University Medical Center & Asan Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients with osteoarthritis in knee joint undergoing elective uni-limb total knee arthroplasty surgery
- Patients provided a written informed consent.
- Patients with s-ferritin < 300 mg/dl (male) or 200 mg/dl (female)
- Patients with preoperative serum hemoglobin concentration >10 g/dL
- Patients with PaO2/FiO2 ratio >150
Exclusion Criteria:
- Patients with history of anaphylaxis, iron overload, active infection.
- Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, recombinant human erythropoietin, or undergoing acute normovolemic hemodilution.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Grupo de control
placebo
|
se administra placebo (solución salina normal) después de la inducción de la anestesia
Otros nombres:
|
|
Experimental: Experimental group
ferric carboxymaltose 1000 mg
|
Ferric carboxymaltose is administered after anesthesia induction
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The changes of Hemoglobin between preoperative and postoperative day 30
Periodo de tiempo: postoperative 30 days
|
intergroup-difference in hemoglobin change
|
postoperative 30 days
|
|
the changes of arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)
Periodo de tiempo: postoperative 5 days
|
intergroup-difference in PaO2/FiO2 ratio
|
postoperative 5 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)
Periodo de tiempo: postoperative 1 day
|
intergroup-difference in PaO2/FiO2 ratio
|
postoperative 1 day
|
|
arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)
Periodo de tiempo: postoperative 3 days
|
intergroup-difference in PaO2/FiO2 ratio
|
postoperative 3 days
|
|
arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)
Periodo de tiempo: postoperative 5 days
|
intergroup-difference in PaO2/FiO2 ratio
|
postoperative 5 days
|
|
serum hemoglobin concentration
Periodo de tiempo: postoperative 1 day
|
Intergroup difference of serum hemoglobin concentration, g/dL
|
postoperative 1 day
|
|
serum hemoglobin concentration
Periodo de tiempo: postoperative 5 days
|
Intergroup difference of serum hemoglobin concentration, g/dL
|
postoperative 5 days
|
|
serum hemoglobin concentration
Periodo de tiempo: postoperative 30 days
|
Intergroup difference of serum hemoglobin concentration, g/dL
|
postoperative 30 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- KonkukUMC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .